U.S. Markets closed
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow 30

    34,584.88
    -166.44 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.96 (-0.91%)
     
  • Russell 2000

    2,236.87
    +3.96 (+0.18%)
     
  • Crude Oil

    71.96
    -0.65 (-0.90%)
     
  • Gold

    1,753.90
    -2.80 (-0.16%)
     
  • Silver

    22.42
    -0.33 (-1.44%)
     
  • EUR/USD

    1.1732
    -0.0040 (-0.3402%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • Vix

    20.81
    +2.12 (+11.34%)
     
  • GBP/USD

    1.3737
    -0.0059 (-0.4286%)
     
  • USD/JPY

    109.8950
    +0.1770 (+0.1613%)
     
  • BTC-USD

    48,613.18
    +597.45 (+1.24%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.62%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

UPDATE 1-U.S. authorizes additional batch of J&J COVID-19 vaccine produced by Emergent

·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(Adds details on authorization, background, share price) 

  July 2 (Reuters) - The U.S. Food and Drug Administration said on Friday it had authorized the use of an additional batch of Johnson & Johnson's one-dose COVID-19 vaccine manufactured at the problem-plagued Baltimore factory of Emergent BioSolutions Inc. 

  The batch of bulk drug substance - which has not yet been put into vials - can make up to 15 million doses of J&J's vaccine, according to a source familiar with the matter. 

  The FDA has now authorized a total of four batches of the vaccine manufactured at the Emergent facility. 

  "While the FDA is not yet ready to include the Emergent BioSolutions plant ... as an authorized manufacturing facility, the agency continues to work through issues there with Janssen and Emergent BioSolutions management," the agency said in a statement, referring to J&J's pharmaceuticals unit. 

  Production of J&J's vaccine at the Baltimore site was halted by U.S. authorities in April following the discovery that ingredients from AstraZeneca's COVID-19 vaccine, also being produced at the plant at the time, contaminated a batch of J&J's vaccine. 

  An FDA inspection of the plant also turned up a long list of sanitary problems and bad manufacturing practices. 

  "As COVID-19 continues to impact countries and cause untold suffering worldwide, we remain committed to producing safe, high-quality vaccines," J&J said in a statement. 

  J&J shares closed up about 2% at $168.98. 

  (Reporting by Dania Nadeem in Bengaluru and Michael Erman in New Jersey; Editing by Devika Syamnath and Bill Berkrot)